Shanghai Shen Lian Biomedical Corporation Class ASSE: 688098

Announcement on Voluntary Disclosure of the Progress in Phase II Clinical Trial for Innovative Drug UB-221 of the Joint-Stock Company

· Issued by Shanghai Shen Lian Biomedical Corporation Class A via Shanghai Stock Exchange
Announcement on Voluntary Disclosure of the Progress in Phase II Clinical Trial for Innovative Drug UB-221 of the Joint-Stock Company

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:
View Attachment

Company analysis